Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||HRAS G12D|
|Therapy||Alpelisib + Tipifarnib|
|Indication/Tumor Type||head and neck squamous cell carcinoma|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|HRAS G12D||head and neck squamous cell carcinoma||sensitive||Alpelisib + Tipifarnib||Preclinical - Cell culture||Actionable||In a preclinical study, the addition of Piqray (alpelisib) sensitized head and neck squamous cell carcinoma cell lines harboring HRAS G12D to treatment with Zarnestra (tipifarnib), resulting in enhanced growth inhibition and increased apoptosis in culture (PMID: 35247914).||35247914|
|PubMed Id||Reference Title||Details|
|(35247914)||Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma.||Full reference...|